KOSDAQIT & Software187220

Dt&C

₩1,744▼ 6.79%2026-11-18 close
Market Cap
₩20.1B
Turnover
₩49,842,143
Volume
30K
Shares out.
11.5M
PER
3.0×
PBR
0.2×
EPS
₩597
Dividend Yield
5.55%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩100 per share · Prices as of the 2026-11-18 close

01

Report overview

Testing core profits versus consolidated losses

The standalone testing business remains profitable, but consolidated results are still weighed down by the bio segment and subsidiary investment, so whether the loss narrowing lasts is the key point to watch.

  1. 1

    Consolidated revenue reached KRW 125.8 billion in 2025, the largest year in 2022–2025, and rose for two consecutive years from 2024 to 2025.

  2. 2

    The operating loss narrowed from KRW 20.7 billion in 2023 to KRW 597 million in 2025, yet the company has posted operating losses for three consecutive years from 2023 to 2025.

  3. 3

    Quarterly operating results swung in 2026, with an operating loss of KRW 1.9 billion in Q1, a loss of KRW 6.81 billion in Q2, and operating income of KRW 976 million in Q3.

  4. 4

    On a standalone basis, first-half 2026 revenue rose 7.9% year on year to KRW 26.75 billion, while operating profit fell 32% to KRW 2.49 billion, according to the company's investor briefing.

  5. 5

    The debt-to-equity ratio rose to 125.7% at end-2025 from 74.2% in 2022, and the company is retiring its convertible bonds.

02

Business structure

Dt&C was founded in 2000 for electromagnetic wave testing and certification and listed on KOSDAQ in 2014. Its core business is testing and certification services covering electromagnetic waves, electrical safety, human exposure to electromagnetic waves and communication standards.

At its first-half 2026 investor briefing, the company said it provides testing and certification across electrical and electronics, automotive, defense, robotics, nuclear power and cybersecurity from its Yongin headquarters and Busan center.

A Seoul test facility, introduced as scheduled for construction in 2026, is part of the planned footprint expansion.

Beyond testing and certification, the portfolio includes bio technology services covering non-clinical and clinical trial work, technology services for automotive electronics, nuclear and defense, and a robotics and parts segment.

On 2025 results, the company said technology services tied to automotive electronics, nuclear and defense grew in both sales and profit, while losses continued in the bio technology services segment.

An external corporate information service described the bio segment as the largest share of revenue, yet first-half 2026 saw falling sales and wider operating losses in that segment. Standalone robotics and parts sales were KRW 1.72 billion in first-half 2026.

Demand for testing and certification arises from product launches and regulatory requirements, so expanding facilities and equipment is a key driver of how much work the company can take on.

Several testing and certification bodies operate in Korea, and the company positions its one-stop service and nationwide footprint as its differentiators. According to company materials, consolidated revenue for 2025 was KRW 125.8 billion, with about 306 employees.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩32.6B-₩1.1B−3.4%
2025Q4₩35.1B₩900M2.6%
2026Q1₩28.4B-₩1.9B−6.7%
2026Q2₩28B-₩6.8B−24.3%
2026Q3₩30.6B₩1B3.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩110.5B₩4.5B₩1.4B4.1%1.4%74.2%
2023₩96.7B-₩20.7B-₩14.8B−21.4%−17.5%104.3%
2024₩111.9B-₩5.7B₩4.5B−5.1%5.0%118.3%
2025₩125.8B-₩600M₩2.1B−0.5%2.2%125.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Consolidated revenue went from KRW 110.5 billion in 2022 to KRW 96.7 billion in 2023, a decline of 12.5%, before rising to KRW 111.9 billion in 2024, up 15.7% year on year, and KRW 125.8 billion in 2025, up 12.4%.

Revenue has grown for two consecutive years from 2024 to 2025, with 2025 the largest year in 2022–2025 and 2023 the smallest. Operating profit was KRW 4.54 billion in 2022, then turned into an operating loss of KRW 20.7 billion in 2023.

The loss continued in 2024 at KRW 5.71 billion and in 2025 at KRW 597 million, with the losses narrowing each year. The operating margin was 4.1% in 2022, -21.4% in 2023, -5.1% in 2024 and -0.5% in 2025.

Profit attributable to controlling shareholders turned to a loss of KRW 14.8 billion in 2023, returned to a profit of KRW 4.5 billion in 2024, and fell 53.2% to KRW 2.11 billion in 2025. Net income including non-controlling interests moved from KRW 2.91 billion in 2024 to a net loss of KRW 771 million in 2025.

In 2025 the controlling shareholders' share was profitable while the consolidated bottom line was a loss, which suggests the non-controlling interests weighed heavily on consolidated results.

On a standalone basis, 2025 revenue was KRW 52.7 billion and operating profit KRW 6.45 billion, a profitable result that contrasts with the consolidated loss.

The debt-to-equity ratio rose from 74.2% in 2022 to 104.3% in 2023, 118.3% in 2024 and 125.7% in 2025, when total liabilities of KRW 146.4 billion exceeded total equity of KRW 116.5 billion. Operating cash flow was KRW 12.8 billion in 2022, KRW 630 million in 2023, KRW 11 billion in 2024 and KRW 11.9 billion in 2025.

Quarterly, an operating loss of KRW 1.11 billion in Q3 2025 gave way to operating income of KRW 926 million in Q4 2025. Operating results then slipped to a loss of KRW 1.9 billion in Q1 2026 and a wider loss of KRW 6.81 billion in Q2 2026, before returning to operating income of KRW 976 million in Q3 2026.

Profit attributable to controlling shareholders reached KRW 6.18 billion in Q1 2026, up 164.5% from the prior quarter, even though the consolidated operating result that quarter was a loss. The company attributed the Q1 consolidated loss to a mix of early-stage costs at some subsidiaries and accounting factors.

The sum of controlling-shareholder net income over the latest four quarters, Q4 2025 through Q3 2026, is KRW 6.87 billion.

05

Industry analysis

The company's main demand sources are electrical and electronics, automotive, defense, robotics, nuclear power and cybersecurity, as outlined in its corporate materials.

On 2025 results, the company pointed to growth in technology services linked to automotive electronics, nuclear and defense, a field that overlaps with certification demand in those industries.

The robotics and parts segment is still a small share of revenue, with standalone sales of KRW 1.72 billion in first-half 2026. The bio segment saw falling sales and wider operating losses in first-half 2026, which makes it the main structural weak point.

Testing and certification in Korea involves several competing bodies, where turnaround time and service scope typically affect which projects are won. The company has presented its one-stop service, nationwide footprint expansion and growth in higher-value projects as ways to strengthen its competitiveness.

Revenue recovered after the 2023 low of KRW 96.7 billion through 2024 and 2025. Quarterly recovery is uneven, however, since Q3 2026 consolidated revenue of KRW 30.6 billion fell 6.1% from a year earlier.

Its position against peers is best read through its footprint, service breadth and the profit structure of the bio segment.

06

Outlook

At its first-half 2026 investor briefing, the company said it would pursue infrastructure expansion and stronger capital spending together.

Press coverage of the briefing described the Busan center as a KRW 13 billion scale project, and noted that higher selling and administrative costs from the expansion could weigh on near-term profit, while margins were expected to widen over the long run.

The standalone operating margin for first-half 2026 was 9.3%, below the 12.2% standalone operating margin for 2025. The Seoul test facility was introduced as scheduled for construction in 2026, so when it begins operating could affect how quickly the company expands the work it can take on.

On financing, the company said it retired 35% of its fifth series of convertible bonds and plans further retirement of the remaining CBs. It also described an employee share purchase program and dividends as part of a shareholder value plan. In January 2026, the company retired 173,088 treasury shares.

When it announced its Q1 2026 results, the company said it would expand higher-value project wins while improving operating efficiency. The next regular filing, the 2026 annual report, will show full-year consolidated operating results and the bio segment's profit and loss.

Whether consolidated operating results move from quarterly swings to a consistent annual trend will be the starting point for judging the effect of the investment program.

07

Valuation

PER
3.0×
PBR
0.2×
ROE
7.2%
EPS
₩597
BPS
₩8,570
Dividend per share
₩100

Market capitalization sits well below the controlling shareholders' equity of KRW 95.9 billion at end-2025, which means the share price is low relative to book net asset value. The price-to-book ratio is also at a low level.

On earnings, controlling-shareholder net income over the latest four quarters totals KRW 6.87 billion, and the price-to-earnings multiple on that base is low. A low multiple does not, however, guarantee earnings stability.

Operating losses continued from 2023 through 2025, operating cash flow was KRW 11.9 billion in 2025 against capital expenditure of KRW 24.5 billion, and the debt-to-equity ratio stood at 125.7% at end-2025, with total liabilities of KRW 146.4 billion above total equity of KRW 116.5 billion.

Taken together, the valuation sits at the low end on book value and earnings, but without confirmed direction in operating profit and cash flow, these comparisons alone make the share price difficult to interpret.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Profitable core business on a standalone basis

The company says its testing and certification core business maintains revenue growth and an operating profit trend. Standalone operating profit turned positive in 2024 and reached KRW 6.45 billion in 2025. Standalone net income for Q1 2026 was reported up 198% year on year.

Narrowing consolidated operating losses

The consolidated operating loss narrowed from KRW 20.7 billion in 2023 to KRW 5.71 billion in 2024 and KRW 597 million in 2025. Profit attributable to controlling shareholders turned to KRW 4.5 billion in 2024. The latest four quarters total KRW 6.87 billion.

Convertible bond retirement and shareholder returns

The company retired 35% of its fifth series of convertible bonds and plans further retirement of the remaining CBs. It describes an employee share purchase program and dividends as part of its shareholder value efforts. In January 2026, it retired treasury shares, reducing the share count.

09

Bear factors

Persistence of consolidated operating losses

Consolidated operating losses have continued for three consecutive years from 2023 to 2025. The Q2 2026 operating loss of KRW 6.81 billion was a sizable quarterly loss. Quarterly profit has swung widely, so one or two profitable quarters are hard to read as a trend.

Bio segment losses and falling sales

The company said losses in its bio technology services segment continued in 2025. An external corporate information service notes that the bio segment holds the largest revenue share, yet sales fell and operating losses widened there in first-half 2026. Whether this segment recovers could shape the direction of consolidated results.

Financial burden and investment costs

The debt-to-equity ratio stood at 125.7% at end-2025, with total liabilities of KRW 146.4 billion. Capital spending has been large relative to operating cash flow of KRW 11.9 billion in 2025, so cash has largely gone into investment.

Standalone operating profit fell 32% in first-half 2026, and press coverage attributed the short-term decline to the investment expansion.

10

Risk factors

Earnings volatility and accounting factors

Quarterly operating results have alternated between losses and profits. In Q1 2026, profit attributable to controlling shareholders moved in a different direction from the consolidated operating loss, which the company attributed to early-stage costs at subsidiaries and accounting factors. The larger the share of subsidiary results, the less core profit may carry through to consolidated results.

Capital structure and convertible bonds

The debt-to-equity ratio rose to 125.7% at end-2025, with total liabilities of KRW 146.4 billion. Convertible bond retirement is under way, but the size of the remaining CBs and the timing of their retirement will determine the financial burden and potential changes in share count. Heavier borrowing could force the company to slow its capital spending.

Investment execution and demand dependence

The KRW 13 billion Busan center investment and the Seoul test facility add depreciation and selling and administrative costs before they start operating. If demand in areas such as defense, nuclear power or automotive electronics slows, utilization of new facilities could fall. A slow recovery in the bio segment could also lengthen the payback period on investment.

11

What to watch next

  1. Around year-end 2026

    Completion and start of operations at the Seoul test facility. Any delay would affect the payback period on investment and the pace of work expansion.

  2. By end-March 2027 (annual report filing deadline)

    Full-year 2026 consolidated operating profit, bio segment results and profit attributable to controlling shareholders in the annual report. It will be the first regular filing to include Q4 2026.

  3. By mid-May 2027 (Q1 quarterly report deadline)

    Q1 2027 consolidated operating results and the scale of early-stage subsidiary costs. This is where to check how the quarterly consolidated result relates to the standalone profit of the core business.

  4. Timing not fixed (to be confirmed on disclosure)

    The size of further retirement of the remaining convertible bonds and the scale of the employee share purchase program. Both directly affect the financial burden and changes in share count.

12

Overall view

Dt&C's consolidated revenue rose from a 2023 low to KRW 125.8 billion in 2025, but operating results only narrowed from an operating loss of KRW 20.7 billion in 2023 to a loss of KRW 597 million in 2025. Operating losses have persisted for three consecutive years from 2023 to 2025.

In 2025, controlling-shareholder net income of KRW 2.11 billion coexisted with a net loss of KRW 771 million, a wide gap between the two measures. The company says its standalone testing core business remains profitable, and standalone operating profit of KRW 6.45 billion in 2025 is cited as support.

Quarterly swings are large, however, as seen in the KRW 6.81 billion operating loss in Q2 2026, so the consolidated trend has not yet settled into one direction.

On the financial side, the debt-to-equity ratio of 125.7% at end-2025 and the ongoing retirement of convertible bonds sit alongside investment expansion that reduced standalone operating profit in first-half 2026.

On valuation, market capitalization sits below controlling-shareholder equity, but without confirmed direction in operating results and cash flow, that comparison alone is hard to interpret.

The next checkpoints are full-year 2026 consolidated operating results in the annual report, the start of operations at the Seoul test facility, and consolidated operating results for Q1 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. comp.fnguide.com
  3. easygongsi.com
  4. moneytoring.ai
  5. digitaltoday.co.kr
  6. dtnc.co.kr
  7. marketin.edaily.co.kr
  8. google.com
  9. news.nate.com
  10. edaily.co.kr
  11. tradingkey.com
  12. tradingkey.com
  13. digitaltoday.co.kr
  14. m.news.nate.com
  15. kr.investing.com
  16. m.news.nate.com
  17. indexbox.io
  18. ilovepcbang.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis